View Rule
View EO 12866 Meetings | Printer-Friendly Version Download RIN Data in XML |
HHS/SAMHSA | RIN: 0930-AA37 | Publication ID: Spring 2023 |
Title: Mandatory Guidelines for Federal Workplace Drug Testing Programs--Oral/Fluid | |
Abstract:
This action proposes to establish the scientific and technical guidelines for the inclusion of oral/fluid specimens in the Mandatory Guidelines for Federal Workplace Drug Testing Programs and standards for certification of laboratories engaged in drug testing for Federal agencies. This final rule would adopt a more efficient method of updating the drug testing panel for the federal workplace drug testing programs. Additional changes subject to public comment include further revisions to the Section 3.4 testing panel and revisions to align the HMG with the final Mandatory Guidelines for Federal Workplace Drug Testing Programs using Urine (UrMG) and the final Mandatory Guidelines for Federal Workplace Drug Testing Programs using Oral Fluid (OFMG), both published in the April 7, 2022 Federal Register (87 FR 20560 and 87 FR 20522,respectively). |
|
Agency: Department of Health and Human Services(HHS) | Priority: Other Significant |
RIN Status: Previously published in the Unified Agenda | Agenda Stage of Rulemaking: Final Rule Stage |
Major: No | Unfunded Mandates: No |
CFR Citation: None (To search for a specific CFR, visit the Code of Federal Regulations.) | |
Legal Authority: sec. 503 of Pub. L. 100-71 5 U.S.C. 7301 |
Legal Deadline:
None |
||||||||||||
Timetable:
|
Regulatory Flexibility Analysis Required: No | Government Levels Affected: None |
Federalism: No | |
Included in the Regulatory Plan: No | |
RIN Data Printed in the FR: No | |
Agency Contact: Ron Flegel Director, Division of Workplace Programs, CSAP Department of Health and Human Services Substance Abuse and Mental Health Services Administration 5600 Fishers Lane, Room 16N01, Rockville, MD 20857 Phone:240 276-2611 Email: ron.flegel@samhsa.hhs.gov |